CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services Drug Reimbursement Review risdiplam
Back to Programs and Services

Drug Reimbursement Review

risdiplam

Last Updated: November 20, 2020
Result type: Reports
Project Number: SR0661-000
Product Line: Reimbursement Review

Generic Name: risdiplam

Brand Name: TBC

Manufacturer: Hoffmann La-Roche Ltd.

Therapeutic Area: Spinal muscular atrophy

Indications: ​For the treatment of spinal muscular atrophy (SMA)

Manufacturer Requested Reimbursement Criteria1: For the treatment of spinal muscular atrophy (SMA)

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 22, 2020
Call for patient/clinician input closedDecember 10, 2020
Submission receivedNovember 19, 2020
Submission accepted-
Submit Feedback